Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Ustekinumab in Plaque Psoriasis (CLARITY)
NCT02826603Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoints: Psoriasis Area and Severity Index 90 Response at 12 weeks and Investigator's Global Assessment modified 2011 0 or 1 Response at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02826603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826603.